Read more

September 08, 2020
5 min read
Save

COLCOT: Early use of colchicine beneficial after MI

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In a substudy of the COLCOT trial, patients with MI benefited the most from colchicine if it was initiated early in their hospital stay, according to data presented at the virtual European Society of Cardiology Congress.

Perspective from Peter Libby, MD

As Healio previously reported, in the main results of COLCOT, patients with MI assigned colchicine, an anti-inflammatory drug traditionally used to treat gout, experienced a 23% reduction in first ischemic CV events and a 34% reduction in total ischemic CV events at 2 years compared with those assigned placebo.

Someone clutching heart
Source: Adobe Stock.

The present analysis of 4,661 patients (mean age, 61 years; 81% men), almost all of whom were taking aspirin and a statin, was presented by Nadia Bouabdallaoui, MD, from the Montreal Heart Institute, and published in the European Heart Journal.

“In this current analysis of COLCOT, we aimed to determine whether time to treatment initiation of colchicine after MI had an influence on its beneficial effects on CV outcomes,” Bouabdallaoui said in a presentation.

Patients assigned colchicine were stratified based on whether they first received colchicine on days 1 to 3 of their hospital stay, on days 4 to 7 or on day 8 or later.

At a median follow-up of 22.7 months, the primary endpoint of CV death, resuscitated cardiac arrest, MI, stroke or urgent hospitalization for angina requiring coronary revascularization was reduced by 48% in patients from the colchicine group who received it within 3 days of admission compared with patients from the placebo group (HR = 0.52; 95% CI, 0.32-0.84), the researchers found.

In contrast, the researchers found the benefits were less marked when colchicine was started at later time points (for example, HR for those who first received it on day 8 or later = 0.82; 95% CI, 0.61-1.11).

The results of the group taking colchicine within 3 days of hospitalization compared with the placebo group were driven by reductions in urgent hospitalization for angina requiring coronary revascularization (HR = 0.35; 95% CI, 0.14-0.88), MI (HR = 0.58; 95% CI, 0.32-1.05) and stroke (HR = 0.21; 95% CI, 0.02-1.81), according to the researchers. The early colchicine group also had reduced risk for any revascularization (HR = 0.63; 95% CI, 0.4-0.97) and the composite secondary endpoint of CV death, cardiac arrest, MI or stroke (HR = 0.55; 95% CI, 0.32-0.95), Bouabdallaoui said.

“We believe that our results support early, in-hospital initiation of adjunctive therapy with colchicine for post-MI prevention,” she said during the presentation.

Reference: